Pancreatic Cancer
Inside-Out Precision for One of the Hardest Cancers to Treat
Focused Treatment Where It’s Needed Most
Pancreatic cancer is one of the most challenging tumors to treat, in part due to its deep anatomical location and proximity to vital structures. The majority of patients present with pancreatic cancer that has spread beyond the pancreas, involving nearby blood vessels, lymph nodes, or distant organs, making them ineligible for surgical resection such as the Whipple procedure – the only potentially curative option currently available. As a result, treatment is often limited to systemic therapies such as chemotherapy, which can help manage the disease but which may cause side effects and impair overall quality of life.
Alpha DaRT was developed to address this unmet need as an inside-out, intratumoral alpha-emitting radiotherapeutic. By delivering treatment directly within the tumor, Alpha DaRT is designed to achieve a highly concentrated local effect within the pancreatic tumor, with the potential to limit exposure to surrounding healthy tissue.
Potential Benefits of Alpha DaRT for Pancreatic Cancer
Clinical research of patients with locally advanced and metastatic pancreatic cancer has shown early indications encouraging overall survival trends and meaningful pain reduction. The data suggest the possibility of not only better local tumor control, but also real improvements in daily function, comfort, and quality of life for patients facing one of the most challenging cancer diagnoses.
Inside-out, intratumoral treatment
designed to deliver therapy directly within the pancreatic tumor, targeting disease at its source
High local dose concentration
enabled by alpha-particle therapy, delivering potent tumor-focused effect
Potential to spare surrounding healthy tissue
an important consideration given the pancreas’ proximity to critical structures
One-session treatment approach
reducing the need for repeated interventions
Alignment with existing clinical workflows
using techniques familiar to oncology teams
Compatibility with systemic therapies
allowing treatment alongside standard treatments such as chemotherapy
Potential for symptom relief
with early clinical experience suggesting pain reduction
Potential to activate the immune system
through localized tumor destruction that may release tumor antigens and support systemic anti-tumor responses
Delivery of Alpha DaRT to Pancreatic Tumors
Alpha DaRT sources can be delivered into pancreatic tumors using established, image-guided approaches, including endoscopic ultrasound (EUS)–guided and percutaneous, externally guided procedures, selected based on tumor anatomy and physician preference. Both methods are built on techniques routinely used in pancreatic cancer care. In each approach, a cartridge-like loading device connects securely to a standard biopsy needle, to load Radium-224 onto the needle tip for precise intratumoral placement.
Endoscopic delivery
In the EUS-guided approach, performed by an experienced endoscopist, an endoscope equipped with an ultrasound probe is advanced through the digestive tract to visualize the tumor in real time and define its dimensions. A standard biopsy needle, pre-loaded with Radium-224, is passed through the endoscope’s working channel and inserted directly into the tumor. The sources are then delivered intratumorally, either by a pushing or a retraction mechanism, designed for precise placement within the tumor volume.
Percutaneous delivery
In the percutaneous approach, used by interventional radiologists, a different delivery system designed specifically for percutaneous access is employed. Using external ultrasound imaging, the physician guides a standard, percutaneous biopsy needle through the skin, then deploys the Alpha DaRT sources directly into the pancreatic tumor.
Frequently Asked Questions about Alpha DaRT for Pancreatic Cancer
Why might someone consider Alpha DaRT as a treatment for pancreatic cancer?
The current standard of care for inoperable pancreatic cancer is chemotherapy, which may only provide limited results. Alpha DaRT has been shown in preliminary research to extend survival in comparison to chemotherapy alone. Because it is designed to deliver a highly concentrated radiation dose directly inside the tumor while limiting exposure to surrounding healthy tissue, and because it may also potentially stimulate the immune system, the Alpha DaRT may offer a compelling treatment option. This is particularly important in pancreatic cancer, where tumors are located deep in the body and close to critical structures.
How is Alpha DaRT delivered in pancreatic tumors?
Alpha DaRT is designed to be delivered directly into pancreatic tumors using image-guided procedures that are commonly used in pancreatic cancer care, such as: Endoscopic ultrasound (EUS)–guided delivery, where a physician uses an ultrasound-equipped endoscope to visualize the tumor and place Alpha DaRT sources through a biopsy needle and Percutaneous delivery, where a physician uses external imaging guidance to insert a needle through the skin and place Alpha DaRT sources into the tumor.
Where can someone find Alpha DaRT treatment for pancreatic cancer in the U.S.?
Alpha DaRT for pancreatic cancer is currently available only through approved clinical trials at select medical centers in the United States. For those who are interested in learning more about participating centers and eligibility may visit www.clinicaltrials.gov. Additional information about ongoing pancreatic cancer studies is available on the Alpha Tau website’s clinical trials section.
Is there already any clinical data on Alpha DaRT in pancreatic cancer?
Yes. Early clinical research in patients with locally advanced and metastatic pancreatic cancer has shown encouraging findings, including trends toward improved overall survival and meaningful reductions in pain.
These early results suggest that Alpha DaRT may help improve local tumor control and quality of life, while ongoing clinical trials continue to evaluate its safety and effectiveness in pancreatic cancer. Results of course may vary and a physician must always be consulted prior to commencing any clinical trial or treatment.